Drivers of melanoma progression under therapy
(collaboration between Physiological Chemistry, Dermatology, Bioinformatics Unit CCC, Human Genetics, Pathology)
Our project aims to identify driver mutations and tumor modifiers of primary and metastatic melanomas, using next generation sequencing of a self-designed melanoma-relevant gene panel, RNA analysis and protein analysis of histological sections. By comprehensive analysis of altered genes on DNA and expression level, we can identify cancer-promoting changes. One focus of the study is the evolution of melanoma during progression and during the course of conventional melanoma therapy with BRAF/MEK and checkpoint inhibitors.
Meierjohann S: Crosstalk signaling in targeted melanoma therapy. Cancer Metastasis Rev. doi: 10.1007/s10555-017-9659-z. (2017) (epub ahead of print)
Haydn JM, Hufnagel A, Grimm J, Maurus K, Schartl M, Meierjohann S: The MAPK pathway as an apoptosis enhancer in melanoma. Oncotarget 5:5040-5053 (2014)
Haferkamp S, Borst A, Adam C, Becker TM, Motschenbacher S, Windhövel S, Hufnagel AL, Houben R,Meierjohann S: Vemurafenib induces senescence features in melanoma cells. J Invest Dermatol. 133:1601-1609 (2013)